Monoclonal remyelination-promoting natural autoantibody SCH 94.03: Pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis

Samuel F. Hunter, David J. Miller, Moses Rodriguez

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Chronic inflammatory demyelination of the central nervous system is usually incompletely repaired. However, we previously reported that in vivo treatment with monoclonal antibody SCH 94.03 (produced using spinal cord homogenate as an immunogen) increased myelin repair 4-fold in the Theiler's virus mouse model of chronic progressive multiple sclerosis (Miller et al., 1994; J. Neurosci. 14: 6230-6238). A major issue regarding site and mechanism of action of this antibody is whether SCH 94.03 enters demyelinated CNS lesions and reacts With oligodendrocytes and myelin. To address this question, we radiolabeled SCH 94.03 and studied its distribution into tissues, pharmacokinetics, and binding to cells within demyelinating spinal cord lesions in vivo. SCH 94.03 distributed widely into extracellular water following intraperitoneal injection and was eliminated with a terminal half-life of 3-4.5 days. Only a portion of the total dose (0.4%) entered brain and spinal cord. SCH 94.03 accumulated 1.5-2.0-fold in brain between 1 and 7 days after injection, but its pharmacokinetics were otherwise similar to those of an isotype control IgMκ antibody. Oligodendrocytes, myelin sheaths and, less frequently, axons were labeled within demyelinating lesions as detected by light and electron microscopic autoradiography. These findings suggest that remyelination-promoting autoantibodies could act within the demyelinating lesion of the central nervous system by binding to the oligodendrocyte, myelin, or axon.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalJournal of the neurological sciences
Volume150
Issue number2
DOIs
StatePublished - Sep 10 1997

Keywords

  • Demyelination
  • Multiple sclerosis
  • Myelin
  • Natural autoantibody
  • Oligodendrocyte
  • Pharmacokinetics
  • Remyelination
  • Theiler's virus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Monoclonal remyelination-promoting natural autoantibody SCH 94.03: Pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this